- Home
- AFJK vs ALVR Comparison
AFJK vs ALVR Comparison
Compare AFJK & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFJK
- ALVR
- Stock Information
- Founded
- AFJK 2023
- ALVR 2013
- Country
- AFJK United States
- ALVR United States
- Employees
- AFJK N/A
- ALVR N/A
- Industry
- AFJK
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AFJK
- ALVR Health Care
- Exchange
- AFJK NYSE
- ALVR Nasdaq
- Market Cap
- AFJK 95.5M
- ALVR 87.7M
- IPO Year
- AFJK 2023
- ALVR 2020
- Fundamental
- Price
- AFJK $10.60
- ALVR $0.55
- Analyst Decision
- AFJK
- ALVR Sell
- Analyst Count
- AFJK 0
- ALVR 5
- Target Price
- AFJK N/A
- ALVR $1.00
- AVG Volume (30 Days)
- AFJK 5.9K
- ALVR 521.6K
- Earning Date
- AFJK 01-01-0001
- ALVR 11-12-2024
- Dividend Yield
- AFJK N/A
- ALVR N/A
- EPS Growth
- AFJK N/A
- ALVR N/A
- EPS
- AFJK 0.27
- ALVR N/A
- Revenue
- AFJK N/A
- ALVR N/A
- Revenue This Year
- AFJK N/A
- ALVR N/A
- Revenue Next Year
- AFJK N/A
- ALVR N/A
- P/E Ratio
- AFJK $40.08
- ALVR N/A
- Revenue Growth
- AFJK N/A
- ALVR N/A
- 52 Week Low
- AFJK $10.15
- ALVR $0.53
- 52 Week High
- AFJK $10.65
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- AFJK N/A
- ALVR 35.53
- Support Level
- AFJK N/A
- ALVR $0.53
- Resistance Level
- AFJK N/A
- ALVR $1.05
- Average True Range (ATR)
- AFJK 0.00
- ALVR 0.11
- MACD
- AFJK 0.00
- ALVR -0.04
- Stochastic Oscillator
- AFJK 0.00
- ALVR 4.42
About AFJK AIMEI HEALTH TECHNOLOGY CO LTD
Aimei Health Technology Co Ltd is a blank check company.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.